Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors

Cancer Research

Volumn 57, Issue 7, 1997, Pages 1217-1221

  Cordon Cardo, Carlos ^a   Zhang, Zuo Feng ^a   Dalbagni, Guido ^a   Drobnjak, Maria ^a   Charytonowicz, Elizabeth ^a   Hu, Shi Xue ^b   Xu, Hong Ji ^b   Reuter, Victor E ^a   Benedict, William F ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER GRADING; CANCER SURVIVAL; CELL DEATH; CELL FUNCTION; CELL PROLIFERATION; COMPLEX FORMATION; DNA DAMAGE; FEMALE; GENE TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TRANSCRIPTION REGULATION; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0030893707     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Kastan, M., Onkyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
2. Zambetti, G., Bargonetti, J., Walker, K., Prives, C., and Levine, A. J. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev., 6: 1143-1149, 1992.
3. El-Deiry, W. S., Tokino, T., Velculescu, V., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
4. Friend, S. H., Horowitz, J. M., Gerber, M. R., Wang, X. F., Bogenmann, E., Li, F. P., and Weinberg, R. A. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc. Natl. Acad. Sci. USA, 84: 9059-9063, 1987.
5. Fung, Y-K., Murphree, A. L., T'Ang, A., Qian, J., Hinrichs, S. H., and Benedict, W. F. Structural evidence for the authenticity of the human retinoblastoma gene. Science (Washington DC), 236: 1657-1661, 1987.
6. DeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C. M., and Livingston, D. M. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell, 58: 1085-1095, 1989.
7. Buchkovich, K., Duffy, L. A., and Harlow, E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell, 58: 1097-1105, 1989.
8. 1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell, 65: 381-393, 1991.
9. DeFeo-Jones, D., Huang, P. S., Jones, R. E., Haskell, K. M., Vuocolo, G. A., Hanobik, M. G., Huber, H. E., and Oliff, A. Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature (Lond.), 352: 251-254, 1991.
10. Chellappan, S. P., Hiebert, S., Mudryj, M., Horowitz, J. M., and Nevins, J. R. The E2F transcription factor is a cellular target for the RB protein. Cell, 65: 1053-1061, 1991.
11. Johnson, D. J., Schwarz, J. K., Cress, W. D., and Nevins, J. R. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature (Lond.), 365: 349-352, 1993.
12. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., and Friend, S. H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Washington DC), 250: 1233-1238, 1990.
13. Greenblatt, M. S., Benett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
14. Kornblau, S. M., Xu, H-J., del Giglio, A., Hu, S-X., Zhang, W., Calvert, L., Beran, M., Estey, E., Andreeff, M., Trujillo, J., Cork, M. A., Smith, T. L., Benedict, W. F., and Deisseroth, A. B. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Res., 52: 4587-4590, 1992.
15. Cordon-Cardo, C., Dalbagni, D., Saez, G., Oliva, M., Zhang, Z-F., Rosai, J., Reuter, V. E., and Pellicer, A. TP53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer, 56: 347-353, 1994.
16. Esrig, D., Spruck, C. H., 3d, Nichols, P., Chaiwun, B., and Cote, R. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143: 1389-1396, 1993.
17. Sarkis, A., Dalbagni, G., Cordon-Cardo, C., Sheinfeld, J., Herr, H., Zhang, Z-F., Fair, W. R., and Reuter, V. E. Detection of p53 mutations in superficial (T1) bladder carcinomas as a marker of disease progression. J. Natl. Cancer Inst., 85: 53-59, 1993.
18. Lipponen, P. K. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int. J. Cancer, 53: 365-370, 1993.
19. Sauter, G., Deng, G., and Moch, H. Physical deletion of the p53 gene in bladder cancer. Am. J. Pathol., 144: 756-761, 1994.
20. Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z-F., Schultz, P. K., Cordon-Cardo, C., and Scher, H. I. The prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant M-VAC. J. Clin. Oncol., 13: 1384-1390, 1995.
21. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S-C., Nichols, P. W., Skinner, D. G., Jones, P. A., and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259-1264, 1994.
22. Ishikawa, J., Xu, H-J., Hu, S-X., Yandell, D. W., Maeda, S., Kamidono, S., Benedict, W. F., and Takahashi, R. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res., 51: 5736-5740, 1991.
23. Presti, J. C., Reuter, V. E., Galan, T., Fair, W. R., and Cordon-Cardo, C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res., 57: 5405-5409, 1991.
24. Cordon-Cardo, C., Wartinger, D., Petrylak, D., Dalbagni, G., Fair, W. R., Fuks, Z., and Reuter, V. E. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl. Cancer Inst., 84: 1251-1256, 1992.
25. Logothetis, C. J., Xu, H-J., Ro, J. Y., Hu, S-X., Sahin, A., Ordonez, N., and Benedict, W. F. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl. Cancer Inst., 84: 1256-1261, 1992.
26. Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., and Weinberg, R. A. Effects of an Rb mutation in the mouse. Nature (Lond.), 359: 295-300, 1992.
27. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
28. Williams, B. O., Remington, L., Albert, D. M., Mukai, S., Bronson, R. T., and Jacks, T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat. Genet., 7: 480-484, 1994.
29. American Joint Committee on Cancer. Manual for the staging of cancer, 4th Ed., tumor-node-metastasis. Committee of the International Union Against Cancer, 1993.
30. Banks, L., Matlashewski, G., and Crawford, L. Isolation of human TP53 specific monoclonal antibodies and their use in the studies of human TP53 expression. Eur. J. Biochem., 159: 529-534, 1986.
31. 1 cells: correlation to changes in total RB protein level. Oncogene, 6: 1139-1144, 1991.
32. Metha, C. R., and Patel, N. R. A network algorithm for performing Fisher's exact test in rXc contingency tables. J. Am. Stat. Assoc., 78: 427-434, 1983.
33. Landis, R. J., Hetman, E. R., and Koch, G. G. Average partial association in three-way contingency tables: a review and discussion of alternative tests. Int. Stat. Rev., 46: 237-254, 1978.
34. SAS Institute, Inc. SAS/STAT user guide, version 6. Cary, NC: SAS Institute, 1990.
35. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
36. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br. J. Cancer, 35: 1-39, 1977.
37. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-220, 1972.
38. Cox, D. R. Partial likelihood. Biometrika, 62: 269-279, 1975.
39. Finlay, C. A., Hinds, P. W., and Tan, T. H. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol., 8: 531-539, 1988.
40. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F., and Levine, A. J. Molecular abnormalities of MDM-2 and P53 genes in adult soft tissue sarcomas. Cancer Res., 54: 794-799, 1994.
41. Xu, H-J., Quinlan, D. C., Davidson, A. G., Hu, S-X., Summers, C. L., Li, J., and Benedict, W. F. Altered retinoblastoma expression and prognosis in early-stage non-small cell lung carcinoma. J. Natl. Cancer Inst., 86: 695-699, 1994.
42. Xu, H-J., Cagle, P. T., Hu, S-X., Li, J., and Benedict, W. F. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. Clin. Cancer Res., 2: 1169-1176, 1995.